Track market-moving stories before they get noisy

Bantamac Capital LLC purchased a new stake in Micron Technology, Inc. (NASDAQ:MU – Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,365 shares of the semiconductor manufacturer’s stock, valued at approximately $2,730,000. Micron Technology comprises 1.4% of Bantamac Capital LLC’s holdings, making the stock its 9th biggest holding.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. State Street Corp increased its position in Micron Technology by 2.1% in the 4th quarter. State Street Corp now owns 52,749,817 shares of the semiconductor manufacturer’s stock valued at $15,061,310,000 after acquiring an additional 1,090,644 shares in the last quarter. Andar Capital Management HK Ltd grew its stake in shares of Micron Technology by 856,960.3% during the second quarter. Andar Capital Management HK Ltd now owns 34,282,413 shares of the semiconductor manufacturer’s stock valued at $39,571,847,000 after purchasing an additional 34,278,413 shares during the last quarter. Norges Bank acquired a new stake in shares of Micron Technology in the fourth quarter valued at approximately $6,433,456,000. Morgan Stanley increased its holdings in shares of Micron Technology by 5.1% in the fourth quarter. Morgan Stanley now owns 16,396,655 shares of the semiconductor manufacturer’s stock valued at $4,679,771,000 after purchasing an additional 794,289 shares in the last quarter. Finally, Northern Trust Corp raised its position in Micron Technology by 1.9% in the 4th quarter. Northern Trust Corp now owns 10,654,349 shares of the semiconductor manufacturer’s stock worth $3,040,858,000 after purchasing an additional 194,550 shares during the last quarter. Institutional investors and hedge funds own 80.84% of the company’s stock.

Insider Activity In other Micron Technology news, EVP Sumit Sadana sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $934.29, for a total value of $14,014,350.00. Following the completion of the sale, the executive vice president owned 191,021 shares of the company’s stock, valued at approximately $178,469,010.09. This represents a 7.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sanjay Mehrotra sold 40,000 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $968.90, for a total transaction of $38,756,000.00. Following the completion of the sale, the chief executive officer owned 264,503 shares in the company, valued at approximately $256,276,956.70. This trade represents a 13.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 177,204 shares of company stock valued at $182,156,264. 0.24% of the stock is currently owned by company insiders.

Micron Technology Stock Performance NASDAQ MU opened at $932.86 on Monday. Micron Technology, Inc. has a 12 month low of $114.25 and a 12 month high of $1,255.00. The stock has a 50-day simple moving average of $951.63 and a 200 day simple moving average of $717.04. The company has a current ratio of 3.42, a quick ratio of 2.98 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $1.05 trillion, a PE ratio of 21.12 and a beta of 2.18. Micron Technology (NASDAQ:MU – Get Free Report) last issued its earnings results on Wednesday, June 24th. The semiconductor manufacturer reported $25.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $21.39 by $3.72. The firm had revenue of $41.46 billion for the quarter, compared to analysts’ expectations of $35.91 billion. Micron Technology had a return on equity of 71.13% and a net margin of 55.91%.The company’s revenue was up 345.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.91 earnings per share. Micron Technology has set its Q4 2026 guidance at 30.000-32.000 EPS. Research analysts forecast that Micron Technology, Inc. will post 72.93 EPS for the current year.

Micron Technology Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Tuesday, July 21st. Investors of record on Monday, July 6th were paid a dividend of $0.15 per share. The ex-dividend date of this dividend was Monday, July 6th. This represents a $0.60 annualized dividend and a yield of 0.1%. Micron Technology’s dividend payout ratio (DPR) is presently 1.36%.

Analyst Upgrades and Downgrades Several research firms have issued reports on MU. Zacks Research downgraded Micron Technology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Sanford C. Bernstein set a $1,300.00 price target on Micron Technology in a research note on Monday, June 22nd. Seaport Research Partners reiterated a “buy” rating on shares of Micron Technology in a report on Friday, August 14th. Deutsche Bank Aktiengesellschaft boosted their price objective on Micron Technology from $1,500.00 to $1,550.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. Finally, Morgan Stanley upped their target price on shares of Micron Technology from $1,050.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Thursday, June 25th. Four investment analysts have rated the stock with a Strong Buy rating, thirty-one have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $1,295.63.

View Our Latest Report on Micron Technology

Micron Technology News Summary Here are the key news stories impacting Micron Technology this week:

Positive Sentiment: AI demand is tightening memory supply. CEO Sanjay Mehrotra said data-center customers want roughly 50% more memory than Micron can currently supply, while Nvidia identified memory availability as a key constraint on AI-system growth. That supports Micron’s pricing power and demand visibility. Micron CEO AI Shift Breaks Traditional Memory Market Cycles Positive Sentiment: Nvidia’s purchasing commitments reinforce the bullish outlook. Nvidia reportedly more than doubled memory-related supplier commitments to $279 billion, potentially benefiting Micron as a major supplier. Micron also has approximately $22 billion in strategic commitments, including contracts extending through 2030. Nvidia Just Validated Micron’s Biggest AI Bull Case Positive Sentiment: Expansion plans strengthen Micron’s long-term positioning. The company is investing $10 billion in U.S. research labs, launching a $250 million venture fund and expanding its workforce-training infrastructure. President Donald Trump’s praise of Micron as one of the world’s “hottest” companies adds political visibility to the investment. Why Micron Stock Didn’t Get a Leg Up From SK Hynix’s Memory Optimism Neutral Sentiment: Analysts and bullish commentators point to surging DRAM and NAND prices, record margins and the possibility that AI demand has made memory cycles less volatile. However, much of this optimism may already be reflected in Micron’s substantial previous gains. Negative Sentiment: Profit-taking and valuation concerns are weighing on the shares. Micron has rallied sharply, encouraging investors to lock in gains even after favorable Nvidia news. A softer technology-market backdrop and concerns about potential U.S. chip tariffs are adding pressure. Why Is Micron Stock Falling Negative Sentiment: Investors remain concerned that the memory supercycle will eventually become cyclical. Increased industry capacity or new competitors could eventually reduce pricing and margins, while current supply shortages may constrain Nvidia’s shipments in the near term. Micron Stock Has Surged 220 Percent Micron Technology Profile (Free Report)

Micron Technology, Inc is a global semiconductor company that designs and manufactures memory and storage solutions. Its product portfolio includes dynamic random-access memory (DRAM), NAND flash memory, solid-state drives (SSDs), memory modules and embedded memory solutions for a wide range of computing and electronic devices. Micron supplies components used in data centers, enterprise and cloud infrastructure, client computing, mobile devices, automotive systems and industrial applications, and also markets consumer-facing products under the Crucial brand.

Founded in 1978 and headquartered in Boise, Idaho, Micron has grown into an international manufacturer with research, development and production facilities across multiple regions.

Featured Articles Five stocks we like better than Micron Technology Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for Micron Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Micron Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Corient Private Wealth LP cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 23.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,758 shares of the biopharmaceutical company’s stock after selling 4,315 shares during the quarter. Corient Private Wealth LP’s holdings in Regeneron Pharmaceuticals were worth $8,579,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at about $5,682,636,000. Dodge & Cox raised its position in shares of Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after buying an additional 45,513 shares during the last quarter. Franklin Resources Inc. grew its stake in Regeneron Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after acquiring an additional 106,861 shares in the last quarter. Nuveen LLC increased its holdings in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 142.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after acquiring an additional 1,144,887 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets Several equities research analysts have weighed in on REGN shares. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Royal Bank Of Canada boosted their price objective on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Truist Financial upped their price objective on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research report on Friday, July 31st. HSBC reduced their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Fifteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $800.36.

Read Our Latest Stock Analysis on Regeneron Pharmaceuticals Trending Headlines about Regeneron Pharmaceuticals Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle? Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice Insider Activity at Regeneron Pharmaceuticals In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at approximately $482,400. This represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock valued at $1,090,030 in the last ninety days. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance NASDAQ:REGN opened at $794.19 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a 50-day moving average of $717.52 and a 200 day moving average of $717.95. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00. The firm has a market cap of $81.77 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 1.35 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the company earned $12.81 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Regeneron Pharmaceuticals Company Profile (Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Featured Articles Five stocks we like better than Regeneron Pharmaceuticals Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Callan Family Office LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 94,188 shares of the healthcare product maker’s stock, valued at approximately $8,547,000.

A number of other large investors have also added to or reduced their stakes in the stock. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter worth about $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.1% Shares of ABT opened at $112.63 on Monday. The firm has a fifty day moving average price of $102.61 and a 200-day moving average price of $100.14. The firm has a market capitalization of $194.89 billion, a P/E ratio of 36.45, a P/E/G ratio of 2.18 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the business earned $1.26 EPS. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year. Abbott Laboratories Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories’s payout ratio is presently 81.55%.

Analysts Set New Price Targets Several research firms have weighed in on ABT. TD Cowen increased their price objective on Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Royal Bank Of Canada restated an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Wells Fargo & Company upped their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, Piper Sandler reissued an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Read Our Latest Analysis on ABT

Trending Headlines about Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns. Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Read More Five stocks we like better than Abbott Laboratories Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Fairtree Asset Management Pty Ltd purchased a new position in shares of Abbott Laboratories (NYSE:ABT – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 21,856 shares of the healthcare product maker’s stock, valued at approximately $1,983,000.

Several other large investors have also made changes to their positions in the business. BlackRock Inc. raised its holdings in shares of Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the last quarter. State Street Corp boosted its holdings in Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after purchasing an additional 1,627,791 shares during the last quarter. Capital International Investors grew its position in Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares during the period. J. Stern & Co. LLP grew its position in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors raised its stake in shares of Abbott Laboratories by 1.0% during the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after buying an additional 400,400 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance NYSE:ABT opened at $112.63 on Monday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The stock’s 50-day moving average price is $102.61 and its 200-day moving average price is $100.14. The stock has a market capitalization of $194.89 billion, a PE ratio of 36.45, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the business posted $1.26 earnings per share. Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year. Abbott Laboratories Announces Dividend The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Analyst Ratings Changes A number of brokerages have recently commented on ABT. UBS Group lowered their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Robert W. Baird began coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target for the company. Bank of America lowered their price objective on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. TD Cowen raised their price objective on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Finally, Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

View Our Latest Stock Report on ABT

Abbott Laboratories News Roundup Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns. Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

See Also Five stocks we like better than Abbott Laboratories Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

E Fund Management Co. Ltd. bought a new position in Broadcom Inc. (NASDAQ:AVGO – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 225,840 shares of the semiconductor manufacturer’s stock, valued at approximately $85,311,000. Broadcom makes up approximately 1.9% of E Fund Management Co. Ltd.’s investment portfolio, making the stock its 15th biggest holding.

Other large investors have also recently bought and sold shares of the company. Cornerstone Advisors LLC bought a new stake in shares of Broadcom in the 2nd quarter worth approximately $92,522,000. Bank of America Corp DE grew its holdings in shares of Broadcom by 1.5% during the 1st quarter. Bank of America Corp DE now owns 58,737,097 shares of the semiconductor manufacturer’s stock valued at $18,179,719,000 after purchasing an additional 894,564 shares during the last quarter. Bartlett & CO. Wealth Management LLC grew its holdings in shares of Broadcom by 129.3% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 110,048 shares of the semiconductor manufacturer’s stock valued at $34,061,000 after purchasing an additional 62,050 shares during the last quarter. First Bank & Trust raised its position in Broadcom by 17.2% in the 2nd quarter. First Bank & Trust now owns 10,503 shares of the semiconductor manufacturer’s stock worth $3,968,000 after purchasing an additional 1,545 shares during the period. Finally, Fifth Lane Capital LP raised its position in Broadcom by 77.8% in the 4th quarter. Fifth Lane Capital LP now owns 4,000 shares of the semiconductor manufacturer’s stock worth $1,384,000 after purchasing an additional 1,750 shares during the period. 76.43% of the stock is owned by institutional investors.

Analyst Ratings Changes AVGO has been the subject of several analyst reports. Wells Fargo & Company restated an “overweight” rating and set a $545.00 price target (up from $430.00) on shares of Broadcom in a research report on Thursday, May 14th. Morgan Stanley set a $502.00 price objective on Broadcom and gave the stock an “overweight” rating in a report on Thursday, June 4th. JPMorgan Chase & Co. boosted their target price on Broadcom from $500.00 to $580.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Zacks Research cut Broadcom from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $400.00 price target on shares of Broadcom in a research report on Wednesday, August 26th. Twenty-nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $491.97.

View Our Latest Stock Report on Broadcom Key Broadcom News Here are the key news stories impacting Broadcom this week:

Positive Sentiment: Mizuho remains bullish ahead of earnings, citing Broadcom’s nearly uninterrupted 30-quarter earnings track record, deeply negative investor sentiment, and the possibility that CEO Hock Tan will directly address concerns about custom ASIC competition and Google’s in-house chips. Mizuho is bullish on Broadcom ahead of Sept. 2 earnings Positive Sentiment: Broadcom’s partnership with OpenAI on the Jalapeño inference chip highlights demand for specialized AI infrastructure. OpenAI says the chip can deliver substantially better performance per watt than comparison systems, potentially supporting Broadcom’s custom-chip and networking growth. Why BNP thinks Jalapeño could benefit Broadcom stock Positive Sentiment: Analysts argue Broadcom offers a better AI risk-reward profile than AMD because of its broader exposure across custom accelerators, networking, and infrastructure software, along with a comparatively lower valuation. Broadcom vs. AMD: Which AI Chip Stock Has the Better Risk-Reward? Positive Sentiment: A new Kyndryl collaboration expands VMware Cloud Foundation’s reach among enterprise customers, reinforcing Broadcom’s private-cloud and software modernization strategy. Broadcom Kyndryl partnership Neutral Sentiment: Royal Bank of Canada reiterated its “Sector Perform” rating, suggesting balanced expectations rather than a strong near-term catalyst. Royal Bank of Canada reiterates Sector Perform Negative Sentiment: Broadcom is reportedly considering $70 billion to $80 billion of debt financing for an AI chip-related transaction involving companies including Anthropic. The potential borrowing could accelerate growth but raises leverage, execution, and repayment risks. Broadcom nears $70B debt financing deal Negative Sentiment: Investors remain concerned that Google’s and other hyperscalers’ internally designed chips could pressure Broadcom’s custom-silicon revenue. Competition from Marvell, NVIDIA, and AMD adds to the risk, while Broadcom’s elevated earnings multiple leaves less room for disappointment. Marvell and Google custom silicon deal Insiders Place Their Bets In other Broadcom news, insider Mark David Brazeal sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $401.33, for a total transaction of $10,033,250.00. Following the completion of the transaction, the insider owned 194,989 shares of the company’s stock, valued at $78,254,935.37. This represents a 11.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gayla J. Delly sold 1,890 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $385.38, for a total value of $728,368.20. Following the transaction, the director directly owned 31,326 shares of the company’s stock, valued at $12,072,413.88. The trade was a 5.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 61,644 shares of company stock worth $24,016,214 in the last quarter. 1.90% of the stock is currently owned by company insiders.

Broadcom Stock Performance Shares of AVGO opened at $368.79 on Monday. The stock has a market capitalization of $1.75 trillion, a P/E ratio of 61.47, a PEG ratio of 0.70 and a beta of 1.45. Broadcom Inc. has a twelve month low of $287.17 and a twelve month high of $495.00. The company has a quick ratio of 2.01, a current ratio of 2.24 and a debt-to-equity ratio of 0.71. The firm has a fifty day simple moving average of $385.07 and a two-hundred day simple moving average of $376.48.

Broadcom (NASDAQ:AVGO – Get Free Report) last released its quarterly earnings data on Wednesday, June 3rd. The semiconductor manufacturer reported $2.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.40 by $0.04. The firm had revenue of $22.19 billion for the quarter, compared to analysts’ expectations of $22.13 billion. Broadcom had a net margin of 38.85% and a return on equity of 41.61%. The company’s revenue for the quarter was up 47.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.58 earnings per share. On average, research analysts anticipate that Broadcom Inc. will post 10.24 EPS for the current year.

Broadcom Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Monday, June 22nd were paid a $0.65 dividend. The ex-dividend date of this dividend was Monday, June 22nd. This represents a $2.60 annualized dividend and a dividend yield of 0.7%. Broadcom’s dividend payout ratio (DPR) is presently 43.33%.

Broadcom Profile (Free Report)

Broadcom Inc (NASDAQ: AVGO) is a global technology company that designs, develops and supplies semiconductor and infrastructure software solutions for a broad range of markets. The company’s semiconductor business provides components and systems for wired and wireless communications, enterprise and cloud storage, networking and broadband access, serving original equipment manufacturers, cloud service providers, telecommunications carriers and industrial customers worldwide. Broadcom is headquartered in Irvine, California, and operates globally with research, development and sales organizations across North America, Europe and Asia.

On the semiconductor side, Broadcom’s portfolio includes system-on-chip (SoC) and application-specific integrated circuit (ASIC) solutions, radio-frequency and connectivity components, Ethernet switching and PHY devices, storage adapters and controllers, optical transceivers and other networking silicon.

See Also Five stocks we like better than Broadcom Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for Broadcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Broadcom and related companies with MarketBeat.com's FREE daily email newsletter.

Abacus FCF Advisors LLC bought a new stake in Broadcom Inc. (NASDAQ:AVGO – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 32,818 shares of the semiconductor manufacturer’s stock, valued at approximately $12,397,000. Broadcom accounts for 2.3% of Abacus FCF Advisors LLC’s investment portfolio, making the stock its 13th biggest position.

Several other large investors have also modified their holdings of the business. ROSS JOHNSON & Associates LLC increased its position in shares of Broadcom by 1,320.0% during the fourth quarter. ROSS JOHNSON & Associates LLC now owns 71 shares of the semiconductor manufacturer’s stock valued at $25,000 after acquiring an additional 66 shares during the last quarter. Networth Advisors LLC lifted its holdings in shares of Broadcom by 546.2% in the 1st quarter. Networth Advisors LLC now owns 84 shares of the semiconductor manufacturer’s stock worth $26,000 after acquiring an additional 71 shares during the last quarter. SWAN Capital LLC boosted its position in shares of Broadcom by 261.9% during the 4th quarter. SWAN Capital LLC now owns 76 shares of the semiconductor manufacturer’s stock worth $26,000 after purchasing an additional 55 shares during the period. Harborfront Financial Group LLC acquired a new stake in Broadcom in the 2nd quarter valued at approximately $38,000. Finally, Camelot Portfolios LLC purchased a new stake in Broadcom in the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 76.43% of the company’s stock.

Analysts Set New Price Targets Several research analysts have recently commented on AVGO shares. Rosenblatt Securities restated a “buy” rating and set a $500.00 price target on shares of Broadcom in a research report on Thursday, June 4th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $515.00 price objective (up from $430.00) on shares of Broadcom in a report on Thursday, June 4th. JPMorgan Chase & Co. raised their price target on shares of Broadcom from $500.00 to $580.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. Mizuho boosted their price target on shares of Broadcom from $480.00 to $530.00 and gave the stock an “outperform” rating in a research note on Thursday, June 4th. Finally, TD Cowen reaffirmed a “buy” rating and set a $500.00 price objective on shares of Broadcom in a research report on Thursday, June 4th. Twenty-nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Broadcom has a consensus rating of “Moderate Buy” and an average target price of $491.97.

Get Our Latest Stock Report on Broadcom Broadcom Price Performance Shares of Broadcom stock opened at $368.79 on Monday. Broadcom Inc. has a 52-week low of $287.17 and a 52-week high of $495.00. The company has a 50 day moving average of $385.07 and a 200 day moving average of $376.48. The company has a quick ratio of 2.01, a current ratio of 2.24 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $1.75 trillion, a P/E ratio of 61.47, a P/E/G ratio of 0.70 and a beta of 1.45.

Broadcom (NASDAQ:AVGO – Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The semiconductor manufacturer reported $2.44 EPS for the quarter, beating analysts’ consensus estimates of $2.40 by $0.04. Broadcom had a net margin of 38.85% and a return on equity of 41.61%. The company had revenue of $22.19 billion for the quarter, compared to the consensus estimate of $22.13 billion. During the same period in the prior year, the firm posted $1.58 EPS. The company’s quarterly revenue was up 47.9% compared to the same quarter last year. As a group, research analysts forecast that Broadcom Inc. will post 10.24 EPS for the current fiscal year.

Broadcom Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Monday, June 22nd were issued a $0.65 dividend. This represents a $2.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Monday, June 22nd. Broadcom’s dividend payout ratio is 43.33%.

Insiders Place Their Bets In other Broadcom news, Director Harry L. You purchased 1,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was bought at an average cost of $373.57 per share, with a total value of $373,570.00. Following the acquisition, the director directly owned 38,466 shares of the company’s stock, valued at approximately $14,369,743.62. This represents a 2.67% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark David Brazeal sold 25,000 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $401.33, for a total value of $10,033,250.00. Following the completion of the transaction, the insider owned 194,989 shares in the company, valued at approximately $78,254,935.37. The trade was a 11.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 61,644 shares of company stock valued at $24,016,214 in the last three months. Corporate insiders own 1.90% of the company’s stock.

Trending Headlines about Broadcom Here are the key news stories impacting Broadcom this week:

Positive Sentiment: Mizuho remains bullish ahead of earnings, citing Broadcom’s nearly uninterrupted 30-quarter earnings track record, deeply negative investor sentiment, and the possibility that CEO Hock Tan will directly address concerns about custom ASIC competition and Google’s in-house chips. Mizuho is bullish on Broadcom ahead of Sept. 2 earnings Positive Sentiment: Broadcom’s partnership with OpenAI on the Jalapeño inference chip highlights demand for specialized AI infrastructure. OpenAI says the chip can deliver substantially better performance per watt than comparison systems, potentially supporting Broadcom’s custom-chip and networking growth. Why BNP thinks Jalapeño could benefit Broadcom stock Positive Sentiment: Analysts argue Broadcom offers a better AI risk-reward profile than AMD because of its broader exposure across custom accelerators, networking, and infrastructure software, along with a comparatively lower valuation. Broadcom vs. AMD: Which AI Chip Stock Has the Better Risk-Reward? Positive Sentiment: A new Kyndryl collaboration expands VMware Cloud Foundation’s reach among enterprise customers, reinforcing Broadcom’s private-cloud and software modernization strategy. Broadcom Kyndryl partnership Neutral Sentiment: Royal Bank of Canada reiterated its “Sector Perform” rating, suggesting balanced expectations rather than a strong near-term catalyst. Royal Bank of Canada reiterates Sector Perform Negative Sentiment: Broadcom is reportedly considering $70 billion to $80 billion of debt financing for an AI chip-related transaction involving companies including Anthropic. The potential borrowing could accelerate growth but raises leverage, execution, and repayment risks. Broadcom nears $70B debt financing deal Negative Sentiment: Investors remain concerned that Google’s and other hyperscalers’ internally designed chips could pressure Broadcom’s custom-silicon revenue. Competition from Marvell, NVIDIA, and AMD adds to the risk, while Broadcom’s elevated earnings multiple leaves less room for disappointment. Marvell and Google custom silicon deal Broadcom Profile (Free Report)

Broadcom Inc (NASDAQ: AVGO) is a global technology company that designs, develops and supplies semiconductor and infrastructure software solutions for a broad range of markets. The company’s semiconductor business provides components and systems for wired and wireless communications, enterprise and cloud storage, networking and broadband access, serving original equipment manufacturers, cloud service providers, telecommunications carriers and industrial customers worldwide. Broadcom is headquartered in Irvine, California, and operates globally with research, development and sales organizations across North America, Europe and Asia.

On the semiconductor side, Broadcom’s portfolio includes system-on-chip (SoC) and application-specific integrated circuit (ASIC) solutions, radio-frequency and connectivity components, Ethernet switching and PHY devices, storage adapters and controllers, optical transceivers and other networking silicon.

Featured Stories Five stocks we like better than Broadcom Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding AVGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Broadcom Inc. (NASDAQ:AVGO – Free Report).

Receive News & Ratings for Broadcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Broadcom and related companies with MarketBeat.com's FREE daily email newsletter.

Growth investors are OK with trading off profits for high revenue growth as long as losses get smaller over time. That setup implies that a company can eventually become profitable.

However, if a company remains unprofitable for 15 years, it's best to stay on the sidelines. Snapchat (SNAP +1.29%) fits that category. It's still unprofitable despite having 971 million monthly active users (MAUs). The stock is down by more than 30% year to date.

Image source: Getty Images.

Margins have been improving, but it's also been too long Snapchat delivered second-quarter results that revealed 19% year-over-year revenue growth and narrowing losses. It's a good combination for any growth stock, but investors have every right to be impatient with a company that has remained unprofitable for 15 years.

Premium Feature

Moneyball Superscore

56/100

Today's Change

(

1.29

%) $

0.07

Current Price

$

5.50

Still, net losses came in at $164 million compared to $1.6 billion in revenue. That's a negative net profit margin of roughly 10%. It's still not growing as fast as Meta Platforms (META -1.19%), which delivered 28% year-over-year revenue growth in Q2 2026.

Snapchat anticipates $300 million to $350 million in adjusted EBITDA in the third quarter. That doesn't translate into positive net income, though it's an improvement from the $250 million in adjusted EBITDA during the second quarter. Leadership anticipates positive net income in 2027. A "multi-year dilution management program" beginning in 2027 may undo some of the benefits of positive net income.

The company has done a good job of keeping costs in control as other tech companies scramble to increase their AI spending. Snapchat may fall behind on compelling long-term opportunities because of that decision, but it's a prudent one given the company's financials.

User activity is declining in key regions One of Snapchat's strengths and weaknesses is its 971 million monthly active users. It's a large user base Snapchat can tap into for additional revenue growth, but that also means the company has fewer opportunities to meaningfully grow its user base.

For instance, Snapchat's 971 million MAUs represent a 4% year-over-year growth rate. It's also adding users at a slower rate. Between Q1 2025 and Q2 2025, Snapchat added 19 million MAUs. Looking at Q1 and Q2 2026, Snapchat added only 15 million MAUs.

The positive year-over-year growth rate also masks declining growth rates in North America and Europe, two of Snapchat's most critical markets. Its daily active users in North America are down by 6% year over year and have been steadily declining for multiple quarters. European DAUs are down by 2% year over year and have been flat for multiple quarters.

The U.S. accounted for 59% of Snapchat's Q2 revenue, and Europe made up 22% of total revenue. Sure, DAUs across the rest of the world continue to grow, but ARPU remains much lower than in the U.S. and Europe. The ARPU for non-U.S. and non-European regions is only $1, while the ARPU is $10.26 in the U.S.

This long-term trend does not look good for Snapchat, and if it's not reversed, potential profits in 2027 may not last for long.

Chasing the highest yield is usually how income investors get burned, but these three NYSE industrials take a different approach that makes their dividend safety almost unfair to competitors.

Income investors often chase yield and get punished for it. The safer path is finding companies whose earnings and free cash flow tower over what they actually pay out, leaving room for raises even when the cycle turns. That is exactly the setup across these three NYSE-listed industrials. Parker Hannifin just delivered fiscal 2026 free cash flow of $3.9 billion against dividends paid of nearly $1 billion, a coverage ratio most high-yielders can only dream about. Here is why these three earn far more than they distribute, and what that means for the checks landing in your account.

Nucor (NUE): Steel’s Cash Machine Keeps Compounding Nucor (NYSE:NUE | NUE Price Prediction) pays a quarterly dividend of $0.56 per share, good for a yield of roughly 0.88% at a recent price of $251.65. The yield is modest, but the coverage is enormous. Nucor earned $4.84 in adjusted EPS in a single quarter against that $0.56 payout, and TTM EPS of $12.42 against an annualized forward dividend of $2.24.

Free cash flow was $829 million in Q2, described by management as its strongest quarter since 2023. Nucor ended the period with approximately $2.7 billion in cash, $3.4 billion in liquidity, and total debt at just 23% of capital, with what management calls the strongest credit ratings of any North American steel producer. The dividend history shows quarterly payments running from 1999 through 2026, with the quarterly amount stepping from $0.50 in 2022 to $0.56 today. That is a long, unbroken record of quarterly dividends and multiple recent increases.

The bull case: shipments hit a record 7.1 million tons, Section 232 tariffs have cut finished-steel imports 25% year-over-year, and CapEx moderation should push free cash flow higher into 2027. Management has committed to returning at least 40% of net earnings to shareholders annually. The risk is unmistakable: steel is cyclical, and pricing can turn quickly if world capacity floods back.

Dover (DOV): Diversified Industrial With a Long Payout Ladder Dover (NYSE:DOV) yields 1.03% at a recent price of $198.68, with a quarterly dividend of $0.52. Adjusted EPS came in at $2.74 in Q2 alone, meaning the quarterly payout consumes less than a fifth of quarterly earnings. TTM EPS of $8.15 against an annualized forward dividend of $2.08 leaves an enormous cushion.

Year-to-date free cash flow of $320 million is up 23% year-over-year, and management guides to full-year FCF at 14% to 16% of revenue. CFO commentary called the balance sheet “a competitive advantage.” The dividend record shows an unbroken ladder of quarterly increases from $0.44 in 2016 up through the current $0.52, with the most recent step coming in the payment dated August 2025.

All five segments posted positive organic growth in Q2 making for a solid bull case, bookings rose 16% year-over-year with a book-to-bill of 1.06, and secular-growth markets like data-center liquid cooling, biopharma, and CO2 refrigeration now represent roughly 25% of the portfolio. However, a facility-consolidation execution issue in refrigeration trimmed organic growth by roughly a point in Q2, a reminder that operational hiccups can bite even a well-run conglomerate.

Parker Hannifin (PH): 70 Straight Fiscal Years of Rising Dividends Parker Hannifin (NYSE:PH) yields 0.73% at a recent price of $995.02, with a quarterly dividend just raised to $2.00. The Q4 filing verified the milestone: 70 consecutive fiscal years of increasing annual dividends, the kind of streak we screen for in our free Dividend Kings report. Coverage is not close: TTM EPS of $28.06, with full-year adjusted EPS of $32.31, against an annualized dividend now running at $7.40.

Cash generation is what makes this attractive. Fiscal 2026 operating cash flow was a record $4.4 billion, free cash flow hit a record $3.9 billion (up 17%), and free-cash-flow conversion reached 107%. Parker returned nearly $2 billion to shareholders across dividends and buybacks and still cut debt by $1 billion in the quarter, taking net leverage to 1.4 times adjusted EBITDA.

The bull case is anchored by aerospace, where segment sales hit a record $1.9 billion at 29.8% margin and backlog reached a record $8.5 billion. Management raised its fiscal 2031 adjusted segment operating margin target to 30%, from 27%. The implied risk comes with integration: pending acquisitions of Filtration Group and CIRCOR’s commercial aerospace business could push net leverage back toward three times before working back down over roughly six quarters.

Bottom Line for Income Investors These three offer modest headline yields paired with the kind of coverage that lets a dividend keep rising through recessions, tariff fights, and CapEx cycles. Nucor’s cash flow inflection, Dover’s broad organic growth, and Parker Hannifin’s 70-year raise streak all point to the same conclusion: earnings and free cash flow well in excess of the payout are the real definition of dividend safety. For retirees prioritizing durability over headline yield, this trio is built for the long haul.

Contact [email protected] for any questions or corrections.

Key Takeaways SCCO plans to invest $20.5B over the next decade, with most capital allocated to projects.Tia Maria, Los Chancas and Michiquillay represent $10.3B in planned investment in Peru.Southern Copper expects production to increase to 1.6M tons by 2033 or 2034. Southern Copper Corporation (SCCO - Free Report) intends to invest $20.5 billion over the next decade to support its long-term outlook, with the bulk of the capital allocated to projects.

Southern Copper has also reaffirmed its dedication to collaborating with Peru's government to drive economic and social progress. This will be achieved by advancing the company’s Peruvian projects, Tía María, Los Chancas, and Michiquillay, which represent a total investment of $10.3 billion.

SCCO expects to spend $1.8 billion on the Tia Maria project located in the Peruvian region of Arequipa, which is designed to produce 120,000 tons of copper cathodes per year. As of June 30, 2026, the project was 42% complete, with $693 million invested and $1.10 billion committed. The company targets start-up for the second half of 2027.

The company expects to invest $2.6 billion in the Los Chancas, which is expected to produce 130,000 tons of copper and 7,500 tons of molybdenum annually from 2031. Michiquillay requires $2.5 billion in investment and expects to produce 225,000 tons of copper annually from 2032 over an initial mine life exceeding 25 years.

In Mexico, El Pilar is moving toward early site work in September 2026 and construction in the first quarter of 2027, with production targeted for the second half of 2029. The project is designed for 36,000 tons of annual copper cathode output.

These projects give Southern Copper multiple sources of organic production growth beyond current mine grades. These developments help reach tangible milestones for the company’s broader expansion program across both operating countries over time. Southern Copper maintains a strong long-term outlook with production expected to increase to 1.6 million tons by 2033 or 2034.

Project Updates of Southern Copper PeersFreeport-McMoRan Inc. (FCX - Free Report) completed the evaluation of a large-scale expansion at El Abra in Chile to define a large sulfide resource that could potentially support a major mill project similar to the large-scale concentrator at Cerro Verde, with an estimated resource of 20 billion recoverable pounds of copper. Freeport-McMoRan expects the expansion to result in the addition of more than 700 million pounds of copper production annually.

Freeport-McMoRan has a strong liquidity profile and generates substantial cash flows, providing ample flexibility to fund expansion projects, reduce debt and enhance shareholder returns.

BHP Group Limited (BHP - Free Report) has copper projects under execution and a pipeline that could deliver around two Mtpa of attributable copper production by the 2030s. BHP Group is planning an Escondida New Concentrator project with a potential $4.4-$5.9-billion investment to replace the aging Los Colorados plant. BHP Group has approved a pre-commitment funding of $0.5 billion (BHP’s share) for the concentrator, which is expected to have a higher production capacity and add 230-270 kt of copper annually.

SCCO’s Price Performance, Valuations & EstimatesSouthern Copper shares have skyrocketed 123.3% year to date compared with the Zacks Mining - Non-Ferrous industry’s surge of 82.4%. During this time, the Basic Materials sector has risen 34.6% and the S&P 500 has rallied 23%.   

Image Source: Zacks Investment Research

The Southern Copper stock is currently trading at a forward 12-month earnings multiple of 29.17X, which is a premium to the industry average of 24.84X.  

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Southern Copper’s 2026 sales is $16.86 billion, indicating a 25.6% year-over-year jump. The consensus mark for the year’s earnings is pegged at $7.61 per share, suggesting a rally of 45.2%.

The Zacks Consensus Estimate for 2027 sales implies an 11.7% year-over-year dip. The same for earnings suggests a fall of 8.2%.

Earnings estimates for 2026 have moved 0.1% south over the past 60 days, while the same for 2027 have moved up 0.3% over the past 60 days.

Image Source: Zacks Investment Research

The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.  

Beacon Pointe Advisors LLC acquired a new stake in Devon Energy Corporation (NYSE:DVN – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 34,688 shares of the energy company’s stock, valued at approximately $1,435,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Kimmeridge Energy Management Company LLC boosted its holdings in shares of Devon Energy by 56.5% in the 4th quarter. Kimmeridge Energy Management Company LLC now owns 8,850,790 shares of the energy company’s stock valued at $324,204,000 after purchasing an additional 3,195,862 shares during the last quarter. LSV Asset Management boosted its position in shares of Devon Energy by 79.6% in the fourth quarter. LSV Asset Management now owns 799,587 shares of the energy company’s stock worth $29,289,000 after buying an additional 354,500 shares during the period. Morningstar Investment Management LLC acquired a new stake in Devon Energy in the fourth quarter valued at approximately $2,089,000. Illinois Municipal Retirement Fund grew its holdings in Devon Energy by 15.5% during the 1st quarter. Illinois Municipal Retirement Fund now owns 194,773 shares of the energy company’s stock valued at $9,801,000 after purchasing an additional 26,209 shares in the last quarter. Finally, NewEdge Wealth LLC grew its stake in shares of Devon Energy by 20.0% during the first quarter. NewEdge Wealth LLC now owns 479,681 shares of the energy company’s stock valued at $24,138,000 after acquiring an additional 80,000 shares in the last quarter. 69.72% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth Several equities research analysts have recently weighed in on the stock. BMO Capital Markets reissued an “outperform” rating on shares of Devon Energy in a research report on Wednesday, June 10th. Morgan Stanley lowered their price target on shares of Devon Energy from $66.00 to $63.00 and set an “overweight” rating for the company in a research report on Friday, June 26th. Raymond James Financial lowered their target price on Devon Energy from $66.00 to $64.00 and set a “strong-buy” rating on the stock in a research report on Thursday, July 16th. Wells Fargo & Company dropped their price target on shares of Devon Energy from $68.00 to $65.00 and set an “overweight” rating on the stock in a research report on Thursday, August 13th. Finally, JPMorgan Chase & Co. cut their price objective on Devon Energy from $62.00 to $55.00 and set an “overweight” rating for the company in a report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Devon Energy currently has an average rating of “Moderate Buy” and a consensus target price of $59.15.

Check Out Our Latest Analysis on DVN Devon Energy Price Performance Shares of DVN opened at $47.42 on Monday. The business’s 50-day moving average is $44.19 and its 200-day moving average is $45.64. The company has a debt-to-equity ratio of 0.24, a current ratio of 0.72 and a quick ratio of 0.67. The company has a market capitalization of $52.16 billion, a price-to-earnings ratio of 11.26, a P/E/G ratio of 1.30 and a beta of 0.38. Devon Energy Corporation has a fifty-two week low of $31.47 and a fifty-two week high of $52.71.

Devon Energy (NYSE:DVN – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The energy company reported $1.57 EPS for the quarter, topping the consensus estimate of $1.40 by $0.17. The business had revenue of $7.42 billion during the quarter, compared to analysts’ expectations of $6.01 billion. Devon Energy had a net margin of 16.67% and a return on equity of 14.93%. The firm’s quarterly revenue was up 73.1% compared to the same quarter last year. During the same period last year, the company posted $0.84 earnings per share. Equities research analysts expect that Devon Energy Corporation will post 5.2 EPS for the current fiscal year.

Devon Energy Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Tuesday, September 15th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 2.7%. Devon Energy’s dividend payout ratio is 30.40%.

Insider Activity In related news, SVP Andrea Alexander sold 18,000 shares of Devon Energy stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $46.74, for a total transaction of $841,320.00. Following the completion of the sale, the senior vice president owned 138,529 shares of the company’s stock, valued at approximately $6,474,845.46. This trade represents a 11.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.58% of the company’s stock.

Devon Energy Company Profile (Free Report)

Devon Energy Corporation (NYSE: DVN) is an independent oil and gas exploration and production company headquartered in Oklahoma City, Oklahoma. The company focuses on the exploration, development, production and marketing of hydrocarbons, including crude oil, natural gas liquids (NGLs) and natural gas. Devon operates as an upstream energy company that acquires, evaluates and develops onshore resource plays using a combination of drilling, completion and production optimization techniques.

Core business activities include identifying and developing energy reserves, operating well programs and managing reservoir performance to generate production and cash flow.

Further Reading Five stocks we like better than Devon Energy Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding DVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Devon Energy Corporation (NYSE:DVN – Free Report).

Receive News & Ratings for Devon Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devon Energy and related companies with MarketBeat.com's FREE daily email newsletter.

Some dividend stocks fold the moment a recession hits, but four consumer staples names kept raising their payouts straight through a housing collapse and a global lockdown without missing a beat. The question now is whether their current yields and…

Consumer staples earn their keep in the ugly years, and four names built their reputations by writing bigger dividend checks straight through the two nastiest downturns of the modern era. Kimberly-Clark, Hormel, McCormick, and Church & Dwight all raised their annual payouts across both the 2008 financial crisis and the 2020 pandemic shock, and their dividend histories back that up on the tape. As a benchmark for the group, Kimberly-Clark’s quarterly dividend has climbed from $0.58 in 2008 to $1.28 in 2026, a slow-motion doubling that survived a housing collapse and a global lockdown without a single cut.

Kimberly-Clark: 54 Years of Raises and a 4.6% Yield Kimberly-Clark (NYSE:KMB | KMB Price Prediction) trades at $108.68 with a dividend yield of 4.62% and an annualized forward dividend of $5.12. The maker of Kleenex, Huggies, and Cottonelle just extended its dividend increase streak to 54 consecutive years, which qualifies it as a Dividend King and covers every recession this century.

Trailing twelve-month EPS of $5.04 against the $5.08 trailing dividend puts the payout ratio near the ceiling on an accounting basis, but cash generation is healthier: management reported Q1 FY26 operating cash flow of $745M and Q2 adjusted operating profit of $757M, up 6.2%. Cash on the balance sheet stands at $956M, up 50.79% year over year. Adjusted gross margin expanded 190 basis points to 38.8% in the latest quarter, and the low beta of 0.276 tells you what income investors already suspected: this stock does not move like the market.

The bull case is a reset year finishing with high-single-digit adjusted EPS growth from continuing operations on a constant-currency basis and a yield well above the S&P 500. However, there is a caveat. A China social media disinformation campaign is dragging diaper sales by roughly 50 basis points, and the pending Kenvue combination adds integration risk to a company already exiting US private-label diapers.

Hormel Foods: A 5.5% Yield From the SPAM Empire Hormel Foods (NYSE:HRL) has been repriced hard. The stock trades at $21.60 after a 16.4% one-month drop, and the sell-off has pushed the dividend yield to 5.49%, its highest in years. Dividend history verifies the theme: quarterly payments rose from $0.185 through 2008 to $0.2325 in 2020 and now sit at $0.2925, or $1.17 annualized.

The pressure shows up in reported EPS, while cash generation remains healthy. TTM diluted EPS of $0.63 reflects a battered Q3 GAAP EPS of $0.11 hit by a $56M Brazil divestiture loss, a $48.2M Indonesia impairment, and a $37.5M litigation settlement. Strip those out and adjusted EPS beat estimates. On cash, fiscal 2025 operating cash flow was $845.3M against $633.2M in dividends, and the most recent quarter produced $240.6M in operating cash flow versus $161M in dividend payouts. Balance sheet cash of $839.6M is up 40.1% year over year.

The bull case is a beaten-down income staple guiding to 6% to 10% adjusted EPS growth in FY26 with a forward P/E of 14. The risk is that the pressured consumer keeps squeezing retail volumes and the portfolio-reshaping charges keep depressing reported earnings.

McCormick: A Spice Aristocrat in a Rough Year McCormick (NYSE:MKC) trades at $54.10, down 17.27% year to date, which has pushed the dividend yield to 3.41%. Dividend history confirms the resilience story: the quarterly payout was raised from $0.22 to $0.24 at the end of 2008 and from $0.62 to $0.68 at the end of 2020. The current quarterly dividend of $0.48 annualizes to $1.92.

Fiscal 2025 operating cash flow was $962.2M against $483M in dividend payouts. In the latest quarter alone, operating cash flow was $379.8M and dividends paid were $129M. Balance sheet cash of $331.2M is up 166.88% year over year, and Q2 adjusted gross margin expanded 270 basis points to 40.2%. The reported trailing P/E of 9 looks eye-catchingly cheap, though it is inflated by a large one-time gain from the McCormick de Mexico consolidation, so the forward P/E of 16 is the cleaner read.

The bull case is a global flavor leader raising FY26 guidance to adjusted EPS of $3.05 to $3.13 while pursuing a proposed Unilever Foods combination with roughly $600M in annual run-rate cost synergies. The risk is the execution: the Consumer segment posted organic volume/mix of negative 1.9%, and higher interest expense from acquisitions and a FY26 tax rate near 24% will pressure reported earnings.

Church & Dwight: Low Yield, Fortress Coverage Church & Dwight (NYSE:CHD) is the growth entry in this bundle. The stock trades at $100.20, up 21.89% year to date, and the dividend yield is 1.18%. The Arm & Hammer parent raised the quarterly payout from $0.08 to $0.09 during 2008, held $0.24 through 2020 after stepping up from $0.2275 in 2019, and now pays $0.3075 per quarter, or $1.23 annualized.

The low yield masks unusually strong safety for this stock. Fiscal 2025 operating cash flow was $1.215B against just $287.2M in dividends, and management guides FY26 operating cash flow to approximately $1.175B. Organic sales grew 5.8% in Q2 FY26, gross margin expanded 240 basis points to 45.4%, and global e-commerce jumped 22.7% to 25.5% of consumer sales. Management raised the FY26 outlook to adjusted EPS of $3.74 to $3.81, representing 6% to 8% growth.

The bull case is a portfolio of power brands (THERABREATH, HERO, ZICAM, BATISTE) throwing off enough cash to fund tuck-in deals and steady raises. However, valuation could raise some concerns with a trailing P/E of 33 and a forward P/E of 27, buyers are paying a premium for the growth, and the recent TOUCHLAND acquisition has taken cash on hand down 72.4% year over year.

How These Four Fit Together These four consumer staples cover the full income spectrum: Hormel at 5.49% for pure yield, Kimberly-Clark at 4.62% for a Dividend King with visible margin expansion, McCormick at 3.41% for a beaten-down aristocrat with an acquisition catalyst, and Church & Dwight at 1.18% for the growth compounder with cash flow to spare. Each one raised its dividend through the 2008 crisis and again through 2020, and each one is doing it again in 2026 (we ranked ten Dividend Kings like these by valuation right now in a free report you can grab here). That is the shared hook: household products people buy in every economic climate, funding raises that keep showing up on schedule.

Contact [email protected] for any questions or corrections.

Benjamin Edwards Inc. lessened its holdings in shares of Applied Materials, Inc. (NASDAQ:AMAT – Free Report) by 3.5% in the second quarter, according to its most recent filing with the SEC. The firm owned 39,111 shares of the manufacturing equipment provider’s stock after selling 1,432 shares during the quarter. Benjamin Edwards Inc.’s holdings in Applied Materials were worth $28,282,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. JFS Wealth Advisors LLC increased its stake in Applied Materials by 4.3% during the 2nd quarter. JFS Wealth Advisors LLC now owns 409 shares of the manufacturing equipment provider’s stock valued at $296,000 after buying an additional 17 shares during the period. Innovative Asset Advisors Group LLC raised its position in shares of Applied Materials by 2.1% during the 2nd quarter. Innovative Asset Advisors Group LLC now owns 961 shares of the manufacturing equipment provider’s stock worth $695,000 after buying an additional 20 shares in the last quarter. Stonebridge Financial Group LLC raised its holdings in Applied Materials by 2.1% during the second quarter. Stonebridge Financial Group LLC now owns 1,003 shares of the manufacturing equipment provider’s stock worth $725,000 after purchasing an additional 21 shares in the last quarter. N.E.W. Advisory Services LLC lifted its position in Applied Materials by 5.9% in the second quarter. N.E.W. Advisory Services LLC now owns 377 shares of the manufacturing equipment provider’s stock worth $273,000 after purchasing an additional 21 shares during the period. Finally, IMG Wealth Management Inc. lifted its position in Applied Materials by 13.0% in the second quarter. IMG Wealth Management Inc. now owns 183 shares of the manufacturing equipment provider’s stock worth $132,000 after purchasing an additional 21 shares during the period. Institutional investors own 80.56% of the company’s stock.

Applied Materials News Roundup Here are the key news stories impacting Applied Materials this week:

Positive Sentiment: Semiconductor and AI demand remains strong: Recent coverage highlights Applied Materials’ $9.12 billion third-quarter revenue, up 25% year over year, and non-GAAP EPS of $3.50, up 41%. Management cited record demand visibility from AI infrastructure, more than 10 new fab projects during the quarter and fourth-quarter revenue guidance of $10.25 billion. The company is also continuing share repurchases and investing $5 billion in its EPIC Center to accelerate semiconductor innovation. The AI Buildout Is Turning Applied Materials Into A Profit Machine Positive Sentiment: New board member adds semiconductor expertise: AMAT appointed Akash Palkhiwala, Qualcomm’s CFO and COO, to its board and Audit Committee. His finance, operations and industry experience could strengthen oversight as Applied Materials pursues growth tied to advanced logic, memory and AI chip production. Applied Materials Appoints Akash Palkhiwala to Board of Directors Neutral Sentiment: Options market signals elevated uncertainty: A new analysis says options pricing for roughly one year ahead implies a particularly wide potential trading range, extending materially below and above the current level. That suggests investors should expect significant volatility rather than providing a clear directional signal. How Far Applied Materials Stock Can Move In A Year Negative Sentiment: CFO share sale may weigh modestly on sentiment: CFO Brice Hill sold 7,500 AMAT shares for approximately $3.6 million, reducing his direct holdings by 5.51%. The sale does not alter the company’s operating outlook, but insider selling can create a limited short-term sentiment overhang. SEC Insider Transaction Filing Applied Materials Stock Performance Shares of AMAT opened at $461.67 on Monday. The company has a 50-day moving average of $550.80 and a two-hundred day moving average of $457.65. The stock has a market cap of $366.38 billion, a price-to-earnings ratio of 39.80, a PEG ratio of 0.99 and a beta of 1.61. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.42 and a quick ratio of 1.79. Applied Materials, Inc. has a one year low of $154.46 and a one year high of $739.67. Applied Materials (NASDAQ:AMAT – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The manufacturing equipment provider reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.10. The business had revenue of $9.12 billion for the quarter, compared to analyst estimates of $8.99 billion. Applied Materials had a net margin of 30.05% and a return on equity of 38.02%. The firm’s revenue was up 24.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.48 earnings per share. Applied Materials has set its Q4 2026 guidance at 3.820-4.220 EPS. On average, equities research analysts expect that Applied Materials, Inc. will post 12.76 earnings per share for the current year.

Applied Materials Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Thursday, August 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, August 20th. Applied Materials’s payout ratio is 18.28%.

Analyst Ratings Changes AMAT has been the topic of several research analyst reports. The Goldman Sachs Group reiterated a “buy” rating and set a $645.00 price target on shares of Applied Materials in a research report on Monday, August 3rd. Raymond James Financial set a $650.00 price objective on Applied Materials in a report on Wednesday, June 10th. Sanford C. Bernstein raised their target price on Applied Materials from $675.00 to $700.00 and gave the company an “outperform” rating in a research note on Friday, August 14th. Wall Street Zen raised Applied Materials from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Mizuho dropped their price target on shares of Applied Materials from $650.00 to $590.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-seven have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $657.76.

Get Our Latest Research Report on AMAT

Insider Buying and Selling In other news, Director Thomas J. Iannotti sold 9,250 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $599.77, for a total value of $5,547,872.50. Following the completion of the sale, the director owned 40,559 shares of the company’s stock, valued at $24,326,071.43. This trade represents a 18.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Prabu G. Raja sold 10,000 shares of Applied Materials stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $633.53, for a total value of $6,335,300.00. Following the transaction, the insider owned 346,642 shares in the company, valued at $219,608,106.26. This represents a 2.80% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 284,192 shares of company stock valued at $172,625,209. 0.30% of the stock is currently owned by company insiders.

Applied Materials Profile (Free Report)

Applied Materials, Inc is a U.S.-based supplier of equipment, services and software used to manufacture semiconductor chips, flat panel displays and other advanced materials. Headquartered in Santa Clara, California, the company designs and sells capital equipment and related technologies that enable production of integrated circuits, display panels and materials used across the electronics supply chain.

Applied Materials’ offerings include process equipment and factory software that support critical steps in device fabrication, such as deposition, etch, implantation, inspection and metrology, as well as systems for packaging and advanced heterogeneous integration.

Further Reading Five stocks we like better than Applied Materials Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for Applied Materials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Materials and related companies with MarketBeat.com's FREE daily email newsletter.

The music publishing branches of Sony Music (6758.T) and Warner Music (WMG.O) have sued Anthropic in California federal court for allegedly misusing their copyrighted ​song compositions to train its Claude AI models.

Sony and Warner said in ‌the complaint, filed on Friday, that Anthropic pirated hundreds of song lyrics and sheet music from The Beatles, Taylor Swift, Michael Jackson and hundreds of other artists to train ​Claude to respond to human prompts.

The lawsuit is the latest in a ​wave of cases brought against tech companies by copyright owners ⁠including authors, publishers, music labels and news outlets over the use of their ​work to train AI systems. Universal Music Group (UMG.AS) sued Anthropic in 2023 over the alleged ​use of copyrighted song lyrics in AI training, in a lawsuit that is still ongoing.

Anthropic became the first AI company to settle one of the disputes last year, when it paid $1.5 ​billion to resolve a class action from a group of authors.

"Anthropic clearly ​considers that to be just the cost of doing business given that its entire business ‌model continues ⁠to be built on copyright theft," Sony and Warner said in their complaint. "And $1.5 billion is obviously not a large enough settlement to deter infringing conduct by a company that has parlayed such mass infringement into a staggering $2-trillion-dollar valuation."

Spokespeople ​for Anthropic, Sony Music ​and Warner Music ⁠did not immediately respond to requests for comment on Monday.

The complaint alleges Anthropic illegally obtained the publishers' lyrics and ​sheet music through torrent downloads to train Claude, and that ​Claude can ⁠reproduce copyrighted lyrics "verbatim" when prompted.

Sony and Warner also said Anthropic used their lyrics to teach Claude to "generate vast quantities of purportedly 'new' AI-generated song lyrics, which compete with ⁠Music ​Publishers’ legitimate copyrighted works as harmful market substitutes."

The ​labels are seeking damages of up to $150,000 for each infringed copyright and a court order barring Anthropic ​from using their works.

Canada Pension Plan Investment Board acquired a new position in shares of IDEX Corporation (NYSE:IEX – Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 16,700 shares of the industrial products company’s stock, valued at approximately $3,790,000.

A number of other hedge funds have also made changes to their positions in IEX. Empowered Funds LLC lifted its stake in IDEX by 3.4% during the first quarter. Empowered Funds LLC now owns 1,646 shares of the industrial products company’s stock worth $298,000 after purchasing an additional 54 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in IDEX by 4.0% in the first quarter. EverSource Wealth Advisors LLC now owns 1,446 shares of the industrial products company’s stock valued at $274,000 after purchasing an additional 56 shares during the last quarter. Evolve Private Wealth LLC increased its stake in IDEX by 2.8% in the first quarter. Evolve Private Wealth LLC now owns 2,125 shares of the industrial products company’s stock valued at $403,000 after purchasing an additional 58 shares during the last quarter. Sanctuary Advisors LLC raised its holdings in IDEX by 2.6% during the first quarter. Sanctuary Advisors LLC now owns 2,443 shares of the industrial products company’s stock worth $463,000 after purchasing an additional 62 shares in the last quarter. Finally, Mackenzie Financial Corp raised its holdings in IDEX by 2.8% during the fourth quarter. Mackenzie Financial Corp now owns 2,562 shares of the industrial products company’s stock worth $458,000 after purchasing an additional 70 shares in the last quarter. Hedge funds and other institutional investors own 97.96% of the company’s stock.

Wall Street Analyst Weigh In IEX has been the subject of several research analyst reports. DA Davidson upped their target price on shares of IDEX from $230.00 to $240.00 and gave the company a “neutral” rating in a report on Thursday, August 6th. Oppenheimer reiterated an “outperform” rating and set a $265.00 price target on shares of IDEX in a research note on Thursday, July 30th. Weiss Ratings raised shares of IDEX from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, July 30th. Royal Bank Of Canada upped their price objective on shares of IDEX from $261.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Finally, TD Cowen raised their price objective on IDEX from $260.00 to $275.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $260.80.

View Our Latest Report on IDEX Insider Transactions at IDEX In other IDEX news, CAO Lisa M. Anderson sold 385 shares of IDEX stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $238.59, for a total value of $91,857.15. Following the transaction, the chief accounting officer directly owned 4,327 shares in the company, valued at approximately $1,032,378.93. The trade was a 8.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.50% of the company’s stock.

IDEX Price Performance Shares of NYSE IEX opened at $230.44 on Monday. The company has a current ratio of 3.05, a quick ratio of 2.15 and a debt-to-equity ratio of 0.46. IDEX Corporation has a twelve month low of $158.19 and a twelve month high of $243.80. The stock has a 50 day moving average of $228.73 and a two-hundred day moving average of $213.77. The stock has a market cap of $16.99 billion, a P/E ratio of 33.16, a P/E/G ratio of 2.17 and a beta of 0.98.

IDEX (NYSE:IEX – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The industrial products company reported $2.32 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.21. The business had revenue of $920.60 million during the quarter, compared to the consensus estimate of $905.38 million. IDEX had a return on equity of 15.69% and a net margin of 14.49%.The company’s revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.07 earnings per share. IDEX has set its FY 2026 guidance at 8.700-8.850 EPS and its Q3 2026 guidance at 2.200-2.250 EPS. On average, research analysts forecast that IDEX Corporation will post 8.82 earnings per share for the current year.

IDEX Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 24th. Shareholders of record on Monday, July 6th were given a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend was Monday, July 6th. IDEX’s dividend payout ratio (DPR) is presently 42.01%.

IDEX Profile (Free Report)

IDEX Corporation is a diversified industrial manufacturer specializing in the design, production and distribution of highly engineered fluidics systems, measurement technologies and safety solutions. The company’s core offerings include positive-displacement pumps, flow meters, valves, sampling systems and analytical instruments that serve a wide range of end markets such as water treatment, chemical processing, energy, food and beverage, and life sciences. Through its focus on precision engineering and proprietary material science, IDEX delivers products designed for reliability in demanding applications.

Operations at IDEX are organized into three principal segments.

Recommended Stories Five stocks we like better than IDEX Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding IEX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEX Corporation (NYSE:IEX – Free Report).

Receive News & Ratings for IDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEX and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Neogen shares climbed 102.8% in a year, far outpacing the industry's 24.7% decline. Food Safety core growth reached 5.8% in fiscal Q4 2026, its highest quarterly rate since fiscal 2023. NEOG plans to raise fiscal 2027 R&D spending about 50%, targeting innovation and pathogen detection. Neogen Corporation (NEOG - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 102.8%, outperforming the industry’s 24.7% decline. The S&P 500 composite has increased 21.4% during the same time frame.

With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.

Neogen develops and markets food and animal safety products. The company’s Food Safety Division markets culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. 

The Animal Safety division provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides and genomics testing services for the global animal safety market. 

Factors Favoring NEOG’s Share Price GrowthNeogen’s share price is trending upward, prompted by its research and development efforts, which include new launches like Neogen MPNTray, the Listeria Right Now molecular detection assay, Igenity BCHF and MDA2 Quantitative Salmonella. The company plans to increase fiscal 2027 R&D spending by about 50%, with investment focused on Petrifilm innovation, digital connectivity, licensed technologies and next-generation pathogen detection and sanitation platforms. 

Investors are also focused on the company’s Food Safety segment’s quarterly performance. In the fourth quarter of fiscal 2026, segment revenues increased 3.1% year over year, while core growth reached 5.8%, the highest quarterly rate since fiscal 2023. Indicator Testing and Culture Media revenues rose 9.5%, while Bacterial and General Sanitation increased 9.9%. The company is also shifting toward global solutions-based selling, with resources focused on strategic accounts, disciplined segmentation and higher-return geographies. It expects this model to deepen portfolio penetration and improve customer engagement. 

Another growth prospective for Neogen is the Animal Safety business, which entered fiscal 2027 with a cleaner supply position after resolving the majority of third-party supplier issues. The company also cited better conditions in production animal markets, with higher meat prices supporting producer profitability and U.S. herd sizes showing signs of stabilization. 

Neogen’s 2022 merger with 3M’s Food Safety business is expected to generate significant long-term value for shareholders of the combined company. The merger continues to strengthen Neogen’s portfolio, with Petrifilm remaining a key asset. The company is shifting Petrifilm production to its Lansing facility, with sellable production expected to begin in November 2026.

Image Source: Zacks Investment Research

Factors That May Offset NEOG’s GainsNeogen remains materially exposed to foreign currency movements because international sales accounted for 51.2% of fiscal 2026 revenues. The company does not hedge foreign currency translation risk, and its primary exposures include the euro, British pound and Mexican peso. Foreign currency losses increased to $5.8 million in fiscal 2026 from $3.7 million in fiscal 2025. The company’s fiscal 2027 guidance assumes a 1% negative currency impact on reported growth based on prevailing exchange rates. This exposure can create volatility in reported revenues and earnings even when underlying demand is stable.

Additionally, the company faces intense competition from businesses ranging from small firms to divisions of large multinational corporations. Some of these organizations have substantially greater financial resources than the company. These could affect the marketability and profitability of Neogen’s products.

As of the end of fiscal 2026, the company held $185.5 million in cash versus approximately $800 million in debt.

A Look at NEOG’s EstimatesThe Zacks Consensus Estimate for fiscal 2027 EPS has moved north 10.7% to 31 cents in the past 30 days.

The company has an estimated long-term EPS growth rate of 10% compared with the industry’s 10.8%. 

Other Key PicksSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Illumina (ILMN - Free Report) .

Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

Illumina, presently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% growth. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.

Latest credit of nearly $12 brings total PFAS settlement proceeds to more than $71 per customer

, /PRNewswire/ -- Tennessee American Water announced that they are applying additional credits to customers' bills as a result of the company's receipt of proceeds from settlements reached with manufacturers of per- and polyfluoroalkyl substances (PFAS). 

Today, Tennessee American Water issued an $11.92 bill credit to all active water customer accounts as of August 28, 2026. The credit distributes recent settlement proceeds the company received from PFAS manufacturers to customers. 

The Tennessee Public Utility Commission approved a plan that enables Tennessee American Water to provide PFAS settlement funds directly to customers through bill credits as the funds are received. Including this latest credit, customers have received a total of over $71 per account from PFAS-related settlements to date.  Tennessee American Water issued a credit of $59.36 to customers in March of this year to all active accounts at that time.  

The company is committed to complying with all drinking water standards and is taking appropriate actions to meet new PFAS regulations as they are implemented. Tennessee American Water is investing over $45 million in capital improvements across their service territories to continue providing safe, clean, reliable and affordable water service. For more information about PFAS and the steps Tennessee American Water is taking to address them, visit the company's PFAS information page. 

About American Water  
American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886 and celebrating 140 years in 2026, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to approximately 14 million people with regulated operations in 14 states and on 19 military installations. American Water's approximately 7,000 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders. For more information, visit amwater.com and join American Water on LinkedIn, Facebook, X and Instagram.   

About Tennessee American Water
Tennessee American Water, a subsidiary of American Water, is the largest regulated water utility in the state with approximately 100 dedicated employees working to provide safe, clean, reliable and affordable water services to approximately 425,000 people in Tennessee and north Georgia. 

For more information, visit www.tennesseeamwater.com and connect with us on Facebook, X, Instagram, LinkedIn and YouTube. 

SOURCE American Water

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Bloom Energy Corporation (NYSE: BE) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bloom Energy securities between February 27, 2026 and July 8, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BE.

Bloom Energy Case Details

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that:

that Bloom Energy obtained scandium through intermediaries who sourced the metal from China;that, as a result, the Company understated the extent to which it relied on scandium from China; andthat, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
What's Next for Bloom Energy Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/BE. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Bloom Energy you have until September 28, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Bloom Energy Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Bloom Energy Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.

Caisse de depot et placement du Quebec acquired a new stake in shares of Fair Isaac Corporation (NYSE:FICO – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 436 shares of the technology company’s stock, valued at approximately $521,000.

A number of other hedge funds also recently made changes to their positions in the stock. Gallagher Fiduciary Advisors LLC purchased a new position in Fair Isaac in the second quarter worth $269,000. Man Group plc bought a new position in Fair Isaac in the second quarter valued at $7,949,000. Councilmark Asset Management LLC purchased a new stake in Fair Isaac during the second quarter valued at about $540,000. Roberts Glore & Co. Inc. IL purchased a new stake in Fair Isaac during the second quarter valued at about $479,000. Finally, Jupiter Topco LLC bought a new stake in Fair Isaac during the second quarter worth about $33,080,000. 85.75% of the stock is owned by institutional investors.

Fair Isaac Stock Up 0.1% NYSE FICO opened at $1,154.38 on Monday. The company has a 50-day simple moving average of $1,174.41 and a two-hundred day simple moving average of $1,174.19. Fair Isaac Corporation has a 12-month low of $870.01 and a 12-month high of $1,998.01. The firm has a market cap of $24.93 billion, a price-to-earnings ratio of 33.34, a PEG ratio of 1.04 and a beta of 1.30.

Fair Isaac (NYSE:FICO – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The technology company reported $12.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.76 by $0.42. The firm had revenue of $674.19 million for the quarter, compared to analysts’ expectations of $679.17 million. Fair Isaac had a negative return on equity of 32.51% and a net margin of 34.05%.The company’s revenue for the quarter was up 25.7% compared to the same quarter last year. During the same period last year, the firm earned $8.57 earnings per share. Fair Isaac has set its FY 2026 guidance at 42.430-42.430 EPS. Equities analysts expect that Fair Isaac Corporation will post 37.37 earnings per share for the current fiscal year. Insider Transactions at Fair Isaac In related news, Director Eva Manolis sold 967 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $1,400.00, for a total transaction of $1,353,800.00. Following the transaction, the director directly owned 498 shares in the company, valued at $697,200. This trade represents a 66.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.02% of the stock is currently owned by insiders.

Analyst Ratings Changes A number of equities analysts have recently issued reports on the company. Royal Bank Of Canada cut their price objective on Fair Isaac from $2,400.00 to $1,525.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Jefferies Financial Group set a $1,675.00 price objective on Fair Isaac in a report on Monday, August 3rd. Bank of America dropped their target price on Fair Isaac from $1,550.00 to $1,400.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Wall Street Zen lowered Fair Isaac from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Finally, Barclays reduced their price target on shares of Fair Isaac from $1,950.00 to $1,700.00 and set an “overweight” rating on the stock in a research report on Monday, August 10th. Eleven research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,553.69.

Read Our Latest Stock Report on Fair Isaac

Fair Isaac Profile (Free Report)

Fair Isaac Corporation, commonly known as FICO, is a data analytics and software company best known for its FICO Score, a widely used credit-scoring system that helps lenders assess consumer credit risk. Founded in 1956 by Bill Fair and Earl Isaac, the company has evolved from its origins in statistical credit scoring to a broader focus on predictive analytics, decision management and artificial intelligence-driven solutions for financial services and other industries. FICO is headquartered in San Jose, California, and operates globally, serving clients across North America, Latin America, Europe, the Middle East, Africa and the Asia-Pacific region.

FICO’s product portfolio centers on analytics and decisioning technologies.

Featured Articles Five stocks we like better than Fair Isaac Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for Fair Isaac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fair Isaac and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Phillips 66 targets refining controllable costs of $5.50 per barrel by 2027, near its current $5.57 level.PSX's more than 200 initiatives focus on energy efficiency, simplification, reliability and capacity use.Phillips 66's Bayway, Ferndale and Wood River projects each target more than $1M in annual operating savings. Phillips 66 (PSX - Free Report) is an integrated downstream energy company with operations spanning midstream, chemicals, refining, marketing and specialties, and renewable fuels. The refiner is targeting annual refining adjusted controllable costs of about $5.50 per barrel in 2027, excluding turnaround expenses and assuming Henry Hub natural gas prices of $3 per million British thermal units. PSX is close to its objective, with second-quarter 2026 refining adjusted controllable costs at $5.57 per barrel.

Management is pursuing more than 200 refining initiatives aimed at lowering operating expenses across the system. These efforts center on energy efficiency, process simplification, reliability and stronger utilization of available processing capacity. Projects at Bayway, Ferndale and Wood River are each expected to reduce annual operating expenses by more than $1 million, supporting Phillips 66’s broader cost-reduction program.

The cost push is supported by strong refinery execution, with PSX reporting 96% crude-capacity utilization and an 86% clean-product yield in the second quarter. The company has streamlined its refining portfolio, improved yields and utilization and continued to pursue low-capital, high-return projects alongside reliability improvements. With current costs already tracking close to target levels and extensive optimization initiatives underway, Phillips 66 is well-positioned to realize its 2027 cost milestone of $5.50 per barrel.

MPC & VLO Highlight Refining Cost DisciplineBeyond Phillips 66, Marathon Petroleum Corporation (MPC - Free Report) and Valero Energy Corporation (VLO - Free Report) highlight how operating efficiency, refinery optimization and disciplined investment can strengthen downstream cost structures and margins.

Marathon Petroleum reported refining operating costs of $5.72 per barrel in the second quarter, higher than the $5.34 per barrel a year earlier, mainly reflecting lower utilization from planned Mid-Continent downtime. The company expects refining operating costs to moderate to $5.60 per barrel in the third quarter, pointing to potential improvement as operations normalize. MPC is pursuing shorter-cycle, high-return projects focused on margin enhancement and cost reduction, alongside refinery investments at Galveston Bay and Garyville scheduled through year-end 2027.

Valero Energy recorded refining operating expenses, excluding depreciation and amortization, at $4.70 per barrel of throughput in the second quarter, down from $4.91 per barrel a year earlier. The refiner processed about 2.95 million barrels per day while generating adjusted refining operating income of $16.56 per barrel, reflecting strong refinery economics alongside cost control. VLO is advancing the $230-million St. Charles Fluid Catalytic Cracking Unit optimization project, which is expected to begin operations in the third quarter of 2026 and enhance the refinery’s ability to produce higher-value products.

PSX’s Price Performance, Valuation & EstimatesPhillips 66 shares have gained 102.7% over the past year compared with the industry’s 82.7% growth.

Image Source: Zacks Investment Research

From a valuation standpoint, PSX trades at a trailing 12-month enterprise-value-to-EBITDA (EV/EBITDA) of 10.96X. This is above the broader industry average of 5.38X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for PSX's 2026 earnings has remained constant over the past seven days.

Image Source: Zacks Investment Research

PSX currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Key Takeaways MTG's NIW rose 8.5% to $17.8 billion, the highest quarterly level since the third quarter of 2022. MTG's IIF increased 2.6% to $304.8 billion, expanding its premium-generating base for future growth. MTG had $2.7 billion of PMIERs excess, while reinsurance reduced PMIERs required assets by 52%. MGIC Investment Corporation (MTG - Free Report) appears well positioned to sustain attractive earnings and capital returns in the near term. However, the earnings mix could shift as mortgage-insurance credit conditions gradually normalize.

New insurance written (NIW) rose 8.5% year over year to $17.8 billion in the second quarter of 2026, the highest quarterly level since the third quarter of 2022, while insurance in force (IIF) increased 2.6% to $304.8 billion. The growth in NIW and IIF provides MTG with a larger premium-generating base and supports future revenue growth.

For MTG, credit normalization refers to a gradual increase in mortgage delinquencies and potential claims as the exceptionally favorable credit performance of recent years moves closer to historical norms. So far, the normalization appears manageable. MTG's primary delinquency rate increased to 2.37% from 2.21% a year earlier, but declined 7 basis points sequentially from 2.44% in the first quarter of 2026. Management expects some seasonal increase in delinquencies in the second half of the year, but current trends do not indicate a material deterioration in credit quality.

MTG also benefits from strong cure activity, favorable performance from newer policy vintages and substantial capital resources. The company had $2.7 billion of PMIERs excess as of June 30, 2026, while its reinsurance program reduced PMIERs required assets by approximately 52%. These factors provide a meaningful cushion against higher delinquencies and claims and help support capital flexibility.

Overall, MTG should be able to sustain attractive earnings and capital returns as long as credit normalization remains gradual rather than developing into a broader deterioration in mortgage credit quality. Improving NIW, a growing IIF portfolio, disciplined expenses, strong capitalization and reinsurance protection provide a solid foundation. However, investors should expect future earnings to rely increasingly on portfolio growth and recurring operating performance rather than exceptionally favorable loss development.

What About Its Peers?Radian Group’s (RDN - Free Report) mortgage-insurance portfolio is exposed to the same gradual normalization in borrower delinquencies and claims, although strong home equity provides an important buffer.

Essent Group's (ESNT - Free Report) significant portion of its portfolio is entering the period when mortgage-insurance claims are typically highest. Essent expects incurred losses and claims to increase as older books mature.

MTG’s Price PerformanceShares of MTG have gained 11.3% over the past year, outperforming the industry.

Image Source: Zacks Investment Research

MTG’s UndervaluationThe stock is undervalued compared with its industry. Its forward price-to-book value of 1.27X is lower than the industry average of 2.67X. It carries a Value Score of B.

Image Source: Zacks Investment Research

Estimate Movement for MTGThe Zacks Consensus Estimate for MTG’s full-year 2026 and 2027 EPS has moved up 6.2% and 4.8%, respectively, in the past 30 days.
The consensus estimate for MTG’s 2027 EPS and revenues indicates a year-over-year increase. 

Image Source: Zacks Investment Research

MTG stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

A post-earnings drop handed one investor a reason to buy more Marvell Technology, not sell it, and a Google warrant that binds a hyperscaler to shareholder returns is only part of why he keeps hitting the buy button.

I keep hitting the buy button on Marvell Technology (NASDAQ:MRVL | MRVL Price Prediction), and last Thursday’s post-earnings drop of -10.28% gave me another window to add. I own this stock because it sits at the intersection of two irreversible build-outs: custom AI accelerators and the optical fabric connecting them. Every quarter the numbers validate why I refuse to trim.

Data Center Numbers That Keep Pulling Me Back Data Center revenue hit $2.1715 billion in Q2 FY27, up 46% year over year, and now sits at 79% of total revenue versus 74% a year earlier. Total revenue landed at $2.739 billion, up 36.55%. Management sees fiscal 2027 revenue growing about 45% to roughly $12 billion and fiscal 2028 revenue growing about 50% year over year. CEO Matt Murphy said “AI-related bookings remain exceptionally robust”. When a company raises the outlook on a business already growing this fast, I add.

Google Warrant Changes the Math Marvell disclosed an expanded custom silicon agreement with Google that includes a warrant allowing Google to acquire up to 7% of Marvell’s shares tied to revenue milestones. A hyperscaler is formally aligning its economics with mine. Custom revenue is expected to more than double year over year in fiscal 2028, and one analyst on the call framed the deal as $120 billion in cumulative revenue over six years at full milestone achievement, a scale Murphy did not push back on. The Celestial AI photonic fabric technology adds to the same story, and the whole trade sits inside a broader data-center buildout we mapped out in a free report on seven non-chipmaker AI infrastructure suppliers.

Margins, Cash, and Buybacks Non-GAAP operating margin expanded to 36.6% from 34.8%, with management guiding into the 38% to 40% long-term range by Q4. Cash sits at $3.93 billion, up 221.2% year over year. The company repurchased $200 million of stock in Q2, on top of $2.04 billion across FY26. Operating cash flow of $605.5 million funds the buyback machine, and net debt to EBITDA of 0.27 times shows the $4.963 billion long-term debt load is manageable.

Why Not Reach for NVIDIA or Broadcom Instead The two names I could buy instead are NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO). Both are excellent businesses. Marvell offers what I want: a concentrated position where 79% of revenue already flows from the data center and a hyperscaler holds a warrant on up to 7% of the shares. Marvell’s forward P/E of 60 pairs with data center growth of 46% year over year and a custom business expected to more than double next year. That is the pure-play exposure I want.

Risk I Refuse to Hand-Wave Customer concentration is real. A handful of hyperscalers drive the bulk of growth, and any could pull volume in-house or shift to a rival. Add trade restrictions on Chinese customers and tariff uncertainty, and the concentration cuts both ways. What keeps me buying is that the Google warrant structurally binds the biggest concentration risk to my side of the table, and demand is broad-based across interconnect, switching, custom silicon, optical DSPs, and CXL memory expansion.

What Keeps My Buy Button Active Shares are down 8.61% over the past week and still up 155.27% year to date at $216.62. With the Investor Day on October 6, 2026 set to detail custom revenue through fiscal 2029, I would rather be early than clever. I keep buying Marvell because the customer, the technology, and the balance sheet are all pointed the same direction, and the market handed me another discount to prove it.

Contact [email protected] for any questions or corrections.

Want Diversified Upside in Biotechnology? Check out LABUArrowhead Pharmaceuticals NASDAQ: ARWR presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycerides and acute pancreatitis events versus placebo. The company said the data were presented at the European Society of Cardiology Congress in Munich and have been accepted for publication in a major medical journal.

Plozasiran, marketed as REDEMPLO for familial chylomicronemia syndrome, or FCS, is approved to reduce triglycerides in FCS patients in the U.S., European Union, Canada, Australia and China. The severe hypertriglyceridemia indication remains investigational and has not been reviewed or approved by regulators, Arrowhead said.

Get ARWR alerts:

Phase 3 results Gerald Watts, Winthrop Professor at the University of Western Australia, presented the findings from the two pivotal trials. SHASTA-3 and SHASTA-4 enrolled adults with severe hypertriglyceridemia, defined as triglyceride levels above 500 milligrams per deciliter. Participants received 25 milligrams of plozasiran or placebo through four subcutaneous injections over 12 months, alongside background dietary and conventional lipid-lowering treatment.

Watts said plozasiran produced triglyceride reductions of about 80% from baseline at three months, with reductions sustained through 12 months. More than 90% of plozasiran-treated patients reached triglyceride levels below 500 milligrams per deciliter, a threshold associated with elevated acute pancreatitis risk. More than half of treated patients achieved normal fasting triglyceride levels below 150 milligrams per deciliter.

Secondary measures also showed reductions in remnant cholesterol, non-HDL cholesterol and apolipoprotein C3, or ApoC3, according to the presentation. Plozasiran is designed to reduce hepatic production of ApoC3, a regulator of triglyceride metabolism.

In a pooled analysis of the two studies, plozasiran reduced cumulative acute pancreatitis events by roughly 80% relative to placebo, Watts said. The presentation cited a 44.1% absolute risk reduction and a number needed to treat of 24 over one year for the overall trial population.

In exploratory analyses of higher-risk groups, the company reported more than a 90% relative reduction in acute pancreatitis among patients with a prior history of the condition. In a smaller subgroup with triglycerides above 880 milligrams per deciliter and prior acute pancreatitis, Arrowhead reported no acute pancreatitis events among plozasiran-treated patients. Watts cautioned that the subgroup involved small numbers and was exploratory.

Safety observations Watts said patient retention exceeded 90% and adherence to the four-dose regimen was nearly 100%. Treatment discontinuations due to adverse events were low and similar between treatment groups, according to the presentation.

The company reported no anaphylaxis, systemic hypersensitivity or meaningful changes in platelet counts, liver enzymes or liver fat fraction relative to placebo. Investigators observed a small increase in measures related to glycemic control in some analyses, though Watts described the change in glycated hemoglobin, or HbA1c, as small and not clinically meaningful at the end of treatment.

Børge Nordestgaard, professor and chief physician at Copenhagen University Hospital, said the glycemic-control observation appeared consistent with the broader ApoC3 inhibitor class. He described the safety profile presented for plozasiran as promising while noting that longer-term follow-up will be needed.

Market focus and regulatory plans Jennifer Hellawell, Arrowhead’s head of clinical development in cardiometabolic disease, said severe hypertriglyceridemia affects approximately 1% of the population, or more than 3 million people in the U.S. The company defines a high-risk segment of about 1 million U.S. patients as those with triglycerides at or above 880 milligrams per deciliter, or those above 500 milligrams per deciliter with a prior history of acute pancreatitis.

Andy Davis, Arrowhead’s head of cardiometabolic commercial operations, said the company intends to initially focus a potential severe hypertriglyceridemia launch on those high-risk patients. Arrowhead has identified more than 20,000 healthcare professionals across lipidology, endocrinology, preventive cardiology, internal medicine and primary care who treat these patients, Davis said.

Vince Anzalone, Arrowhead’s senior vice president of finance and investor relations, said the company remains on schedule to file a supplemental new drug application seeking approval for plozasiran in severe hypertriglyceridemia before year-end. Arrowhead recently purchased a priority review voucher, which Anzalone said could accelerate the potential U.S. review timeline. Subject to a positive regulatory review, the company is targeting a potential launch in 2027.

Arrowhead estimates the U.S. severe hypertriglyceridemia opportunity could represent $3 billion to $4 billion in annual sales over the long term. The company also highlighted other cardiometabolic programs, including zodasiran for homozygous familial hypercholesterolemia and ARO-DIMER-PA, an investigational dual-targeting therapy for mixed hyperlipidemia.

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Key Takeaways GEHC adds Vivid Explorer, Vivid Advanced and Vivid Focus to expand cardiovascular imaging options.AI-enabled tools and cSound imaging aim to simplify cardiac measurements and enhance visualization.The new Vivid systems have CE Mark approval, while FDA 510(k) clearance remains pending. GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced three additions to its Vivid cardiovascular ultrasound portfolio — Vivid Explorer, Vivid Advanced and Vivid Focus — designed to support cardiac imaging and workflow needs across different care settings. The systems are being showcased at the European Society of Cardiology Congress 2026 in Munich, Germany.

Per management, the company developed the new Vivid systems after working closely with care teams across echo labs, cardiology practices and interventional settings. Building Vivid Explorer, Vivid Advanced and Vivid Focus on the same technology foundation as Vivid Pioneer enables GE HealthCare to address the distinct needs of each setting while delivering a consistent Vivid imaging and user experience.

GEHC Stock Trend Following the NewsGEHC stock has lost 1% since the announcement on Friday. Year to date, the stock has fallen 12.6% compared with the industry’s 15.6% decline. However, the S&P 500 has risen 12.2% in the same timeframe.

The expansion of the Vivid portfolio could strengthen GE HealthCare’s position in the cardiovascular ultrasound market by addressing a broader range of clinical environments. The introduction of AI-enabled workflow tools, advanced imaging capabilities and a common technology platform may support adoption among hospitals, cardiology practices and echo labs, creating additional growth opportunities for GEHC in medical imaging.

GEHC currently has a market capitalization of $32.40 billion.

Image Source: Zacks Investment Research

More on the Vivid PortfolioVivid Explorer is designed for high-volume echo labs and routine interventional procedures, offering 4D, multi-plane and 2D imaging across transthoracic echocardiography (TTE), transesophageal echocardiography (TEE) and intracardiac echocardiography (ICE), along with AI and automation features.

Vivid Advanced targets mid-size hospitals and cardiology practices requiring comprehensive cardiac imaging. The system supports vascular, abdominal and soft-tissue examinations.

Vivid Focus brings cSound imaging technology to everyday cardiac imaging and includes the new 4Sc-RS probe, AI-enabled workflow tools and support for vascular, abdominal and soft-tissue exams. The portfolio also includes Vivid iq, a portable ultrasound system offering advanced cardiovascular, abdominal and musculoskeletal imaging capabilities.

All three new systems use cSound, a software-based imaging architecture designed to enhance contrast, resolution and tissue visualization. AI-enabled tools, including AI Auto Measure 2D, Easy AutoEF, Easy AFI LV and AI Cardiac Auto Doppler, are designed to reduce manual steps and simplify cardiac measurements.

GE HealthCare also introduced EchoPAC Software Only v211, enabling clinicians to review, analyze and quantify studies remotely or on-site using workflows consistent with the Vivid systems. The new Vivid systems and EchoPAC Software Only v211 have received CE Mark, while FDA 510(k) clearance remains pending.

Industry Prospects Favoring the MarketGoing by the data provided by Grand View Research, the global cardiovascular ultrasound market is predicted to be valued at $3.40 billion in 2026 and is expected to witness a CAGR of 4.7% through 2033.

Factors like the rising prevalence of cardiovascular diseases, advancements in ultrasound imaging technologies and growing demand for non-invasive diagnostic procedures are boosting the market’s growth.

Other NewsGE HealthCare recently introduced the LOGIQ e family, including LOGIQ e Xi and LOGIQ e Si, compact laptop ultrasound systems designed for fast, confident imaging across care settings. The systems combine console-level performance, portability, AI-powered features and workflow tools for flexible point-of-care use.

GE HealthCare also launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio. The FDA-cleared and CE-marked solutions support supplemental screening for women with dense breasts, standardized 3D ultrasound acquisition, remote reading and streamlined exam review across multi-site networks.

GEHC’s Zacks Rank & Other Key PicksCurrently, GEHC carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .

Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

Key Takeaways Hasbro shares gained 10.8% in three months as Magic strength and cost savings improved operating momentum.Wizards revenues rose 27% as Magic climbed 32%, helping the franchise top $500 million in quarterly sales.Hasbro raised its 2026 outlook to 5-7% revenue growth and a 25-26% adjusted operating margin. Shares of Hasbro, Inc. (HAS - Free Report) have climbed 10.8% in the past three months, reflecting improving investor confidence in the company’s operating momentum. The stock has outperformed the Zacks Toys - Games - Hobbies industry’s 8.9% gain, the Zacks Consumer Discretionary sector’s 0.6% rise and the S&P 500’s 0.7% return over the same period.

Hasbro’s second-quarter fiscal 2026 results benefited from strong momentum in Magic: The Gathering, successful new releases and robust player demand. Wizards of the Coast benefited from strength in tabletop gaming, digital and licensed gaming, expanding distribution and a favorable business mix. Cost-transformation initiatives and supply-chain efficiencies provided additional support to profitability.

However, investor sentiment remains tempered by the impairment associated with Hasbro’s decision to refocus its Digital Games portfolio. Consumer Products profitability has also faced pressure from tariffs, higher input costs, royalties and unfavorable expense timing. Against this backdrop, should investors buy, hold or sell HAS shares?

HAS’ 3-Month Price Performance

Image Source: Zacks Investment Research

Over the past three months, Hasbro has outpaced Six Flags Entertainment Corporation (FUN - Free Report) , whose shares declined 22.7%, and Mattel, Inc. (MAT - Free Report) , which gained 1.9%. However, HAS has lagged JAKKS Pacific, Inc. (JAKK - Free Report) , which rose 16.5% in the same time frame.

HAS’ Digital Impairment, Tariffs and Cyber Disruption Weigh on ResultsDespite strong top-line growth, Hasbro’s second-quarter profitability faced several pressures. A non-cash impairment tied to the refocusing of its Digital Games portfolio weighed on Wizards of the Coast and Digital Gaming profitability. The segment’s operating margin declined to 40.7% from 46.3% a year earlier. At the consolidated level, adjusted operating margin slipped to 24.8% from 25.2%, while adjusted earnings per share declined to $1.28 from $1.30 despite solid revenue growth.

Consumer Products also remained under pressure from higher input costs, royalties, tariffs and the timing of operating expenses. Operational-excellence initiatives helped offset some oil and input-cost inflation, but normal seasonality and entertainment-related mix shifts continued to weigh on profitability.

The unauthorized network-access incident added further pressure by disrupting order processing, shipping and invoicing, particularly within Consumer Products. Hasbro also incurred recovery, forensic and remediation expenses, with some additional costs expected. Geographic performance remained uneven, as strength in North America was offset by weakness in Europe, Asia Pacific and Latin America. Marvel and Star Wars demand provided support, but lower licensing revenues were an offset. Entertainment also remained soft because of the timing of streaming renewals and other content deals, pressuring revenues and operating profit.

Magic Momentum and Broader Brand Strength Drive Robust GrowthMagic: The Gathering remains Hasbro’s strongest growth catalyst. Wizards of the Coast and Digital Gaming revenues increased 27% in the second quarter, driven by 30% growth in Tabletop Gaming, while Magic itself rose 32%. Strong demand for Secrets of Strixhaven and Universes Beyond Marvel Super Heroes helped Magic surpass $500 million in quarterly revenues for the first time. Favorable scale and mix also supported Wizards’ operating profit despite the Digital Games impairment.

Magic’s momentum extends beyond individual releases. The franchise continues to benefit from an expanding player base, broader distribution and higher initial print runs designed to better meet demand. Improved manufacturing and supply-chain execution, along with additional printing capacity, should further support growth.

Digital and licensed gaming offer another growth avenue, with Monopoly Go! contributing $44 million in the second quarter. Hasbro is concentrating digital investments around Magic, Dungeons & Dragons, owned platforms and higher-conviction titles while increasingly using co-development and co-publishing partnerships to improve efficiency. Consumer Products revenues increased 5%, supported by stronger North American demand, favorable retail-order timing and strength in Marvel and Star Wars products. Product innovation, licensing expansion and momentum across Hasbro’s GEM2 categories provided additional support.

Cost Savings, Cash Flow Strength & Raised Outlook Support GrowthHasbro’s operational transformation continues to provide an important offset to inflation and investment spending. The cost-transformation program generated $70 million of savings in the first half, helping adjusted operating profit increase 21% and adjusted operating margin expand 150 basis points.

Cash generation also improved sharply, with first-half operating cash flow rising to $604 million from $209 million. Hasbro used its stronger cash flow to reduce debt, prefund maturities and return $239 million to its shareholders through dividends and share repurchases.

Strong first-half execution prompted management to raise its 2026 outlook. Hasbro now expects revenues to grow 5-7% in constant currency, an adjusted operating margin of 25-26% and adjusted EBITDA of $1.45-$1.50 billion. Wizards remains the key growth engine, while recovering cyber-related sales, holiday innovation and further cost productivity should support Consumer Products in the second half.

Earnings Estimate Revision of HAS StockHAS’ earnings estimates for 2026 and 2027 have trended upward over the past 30 days to $6.18 and $6.56 per share, respectively. The revised estimates imply year-over-year earnings growth of 7.4% and 11.6%, respectively.

Image Source: Zacks Investment Research

In comparison, Mattel’s earnings are projected to decline 6.4% year over year, while earnings for Six Flags Entertainment and JAKKS Pacific are expected to grow 78.9% and 52.5%, respectively.

HAS Stock Trades at a PremiumHAS stock is currently trading at a premium, with a forward 12-month price-to-earnings (P/E) ratio of 14.64, as shown in the chart below. The premium valuation reflects investor expectations surrounding the continued strength of Magic, improving Consumer Products trends, cost efficiencies and stronger cash generation. However, the premium also leaves less room for execution setbacks. Digital Gaming investment and impairment-related concerns, Consumer Products margin pressure, tariffs and lingering costs associated with the cyber incident remain important risks.

HAS P/E Ratio (Forward 12 Months)

Image Source: Zacks Investment Research

ConclusionHasbro’s growth outlook is supported by exceptional momentum in Magic: The Gathering, broader Wizards of the Coast strength, improving Consumer Products revenues and continued expansion of digital and licensing opportunities. Cost-transformation initiatives, stronger cash flow and the raised 2026 outlook add further support, while upward earnings estimate revisions reinforce improving fundamentals.

Nonetheless, several challenges warrant caution. Consumer Products profitability remains pressured by tariffs, higher input costs and royalties, while the Digital Games impairment highlights execution risks associated with Hasbro’s gaming investments. The company also continues to navigate cyber-related costs and weakness in Entertainment. Following the recent share-price rally, HAS’ premium valuation suggests that some of the improving fundamentals are already reflected in the stock. The combination of strong growth drivers and lingering margin and execution risks supports a hold stance rather than an aggressive entry at current levels.

HAS stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways Quanta's backlog hit $53.4B, up 49% year over year, as data centers and grid projects drive demand.PWR expects 2026 revenues of $39.3-$39.7 billion and adjusted EPS of $16.45-$16.95.Jacobs' backlog reached $28.9B, while the data center business grew more than 100% year over year. Infrastructure-services companies like Quanta Services, Inc. (PWR - Free Report) and Jacobs Solutions Inc. (J - Free Report) operate in a space involving engineering, construction and large-scale capital projects, offering investors exposure to long-term infrastructure spending and electrification. Benefiting from the mega public infrastructure spending cycle, these two market giants are shuffling between market opportunities amid a shaky geopolitical scenario.

Quanta is a leading provider of electric power and utility infrastructure solutions, with a strong focus on transmission, distribution and large-scale energy projects. Meanwhile, Jacobs offers professional, technical and construction services to industrial, commercial and governmental clients.

Let’s closely compare the fundamentals of the two infrastructure stocks to determine which one is a better investment now.

The Case for Quanta StockQuanta’s mix across transmission and distribution, grid hardening, renewable integration and generation gives it multiple paths to participate as those plans become multi-year capital programs. The ongoing expansion of data centers, grid modernization, renewable generation and advanced manufacturing is driving customers to undertake larger, multi-year infrastructure programs. These favorable trends helped drive total backlog to a record $53.4 billion as of June 30, 2026, up 49% year over year from $35.8 billion in June 2025. Management believes the company is still in the early stages of the current demand cycle, with larger utility-generation and technology/load center programs expected to build over the coming years.

Additionally, PWR’s acquisition strategy is creating another growth avenue while complementing organic opportunities. Acquisitions of Phalcon, Enerfab, Percheron and PSD expand its electrical, mechanical, fabrication, engineering and front-end capabilities while broadening exposure to data centers, power generation, advanced manufacturing, utilities and other critical infrastructure. Management expects the four acquisitions to contribute $1.2-$1.4 billion in revenues and $120-$140 million in adjusted EBITDA in 2026, with their contribution reflected in the raised full-year outlook.

Quanta now forecasts consolidated revenues of $39.3-$39.7 billion (compared with the prior expectations of $34.7-$35.2 billion) and adjusted EPS of $16.45-$16.95 (compared with the earlier projection of $13.55-$14.25). Moreover, adjusted EBITDA is projected to be $4.09-$4.21 billion, up from the earlier expectation of $3.49-$3.65 billion.

The company’s strong project execution capabilities remain a key competitive advantage, supporting both customer retention and long-term growth, besides market tailwinds. Moreover, the combination of liquidity, improving leverage, cash generation and disciplined capital allocation gives Quanta the capacity to pursue acquisitions, invest in growth and continue returning capital to shareholders. Yet, management continues to identify weather, regulation, permitting and project timing as factors that can alter revenues, work mix and margins.

The Case for Jacobs StockJacobs continues to benefit from long-term structural demand across data centers, semiconductors, water infrastructure, transportation and energy & power, reporting more than 100% year-over-year growth in its data center business, supported by accelerating AI investments and strong hyperscaler demand. As of the third quarter of fiscal 2026, backlog reached a record $28.9 billion, up 27.3% year over year from $22.7 billion.  During the third quarter of fiscal 2026, direct AI build-out activity represented 11% of adjusted net revenues, up about 100 basis points sequentially. Management expects data center and semiconductor growth to continue and believes its addressable market is expanding as clients seek advisory, design, digital twin and full program delivery capabilities from a single provider.

Moreover, Jacobs’ “Challenge Accepted” strategy continues to shift the portfolio toward science-based consulting, digital delivery and full lifecycle program management. Full ownership of PA Consulting expands the company’s presence in digital transformation, defense, regulated infrastructure and complex consulting assignments. PA Consulting backlog reached $459 million as of the third quarter of fiscal 2026, up 9.3% year over year, supporting management’s confidence in the segment’s opportunity pipeline following the acquisition of the remaining ownership stake.

Owing to improving trends, Jacobs raised the midpoint of its fiscal 2026 outlook. The company now expects adjusted earnings between $7.20 and $7.30 per share, compared with the previous range of $7.10-$7.35. Adjusted net revenue growth is projected at 9.5-10%, up from the prior 8-10.5% range. The adjusted EBITDA margin is expected between 14.7% and 14.8% (compared with 14.6-14.9% expected earlier).

However, with Jacobs’ infrastructure and consulting operations remaining exposed to government budgets, regulatory priorities and project approval cycles, there exist revenue flow risks. Besides, exposure to large projects also creates quarterly volatility in gross revenues and book-to-bill measures. Delays, scope changes or inaccurate cost estimates could weaken profitability and cash collection.

Stock Performance & ValuationAs witnessed from the chart below, in the year-to-date period, Quanta’s share price performance is above Jacobs’ and the broader Construction sector.

Image Source: Zacks Investment Research

Considering valuation, over the last five years, Quanta has been trading above Jacobs on a forward 12-month price-to-earnings (P/E) ratio basis.

Image Source: Zacks Investment Research

Overall, from these technical indicators, it can be deduced that PWR stock offers an increasing growth trend but with a premium valuation, while J stock offers a diminishing growth trend with a discounted valuation.

Comparing EPS Estimate Trends: PWR vs. JThe Zacks Consensus Estimate for PWR’s 2026 and 2027 earnings has trended upward in the past 30 days to $16.37 and $18.96 per share, respectively. The revised estimates for 2026 and 2027 imply year-over-year growth of 52.3% and 15.8%, respectively.

PWR's EPS Trend

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for J’s fiscal 2026 and fiscal 2027 earnings has increased in the past 30 days to $7.26 and $8.28 per share, respectively. The revised estimates for fiscal 2026 and fiscal 2027 imply year-over-year growth of 18.6% and 14%, respectively.

J's EPS Trend

Image Source: Zacks Investment Research

Return on Equity (ROE) of PWR & J StocksJacobs’ trailing 12-month ROE of 23.96% exceeds Quanta’s average, underscoring its efficiency in generating shareholder returns.

Image Source: Zacks Investment Research

Should Investors Invest in PWR Stock or J Stock?Quanta’s growth is being supported by data-center expansion, grid modernization, electrification and power-generation demand, enabling it to raise its 2026 outlook significantly, with adjusted EPS now projected at $16.45-$16.95. The consensus estimate implies 52.3% and 15.8% earnings growth in 2026 and 2027, respectively, while recent acquisitions should further strengthen its capabilities and revenue base.

Jacobs also benefits from robust structural demand, particularly in data centers and semiconductors, with direct AI build-out activity expanding rapidly. The company has also raised its fiscal 2026 outlook. However, its earnings growth trajectory is comparatively slower, with the consensus estimate pointing to 18.6% and 14% growth for fiscal 2026 and 2027, respectively.

Notably, PWR stock currently trades at a premium valuation compared with J stock, while the latter boasts a higher 23.96% ROE than the former. Nevertheless, Quanta’s accelerating backlog, stronger earnings growth, raised outlook and the current Zacks Rank #1 (Strong Buy) outweigh its premium valuation, compared with Jacobs, which currently carries a Zacks Rank #3 (Hold). Thus, PWR stock appears to be a more compelling choice for growth-oriented investors over J stock now. You can see the complete list of today’s Zacks #1 Rank stocks here.